Session Title: AMD I
Session Date/Time: Friday 12/09/2014 | 08:00-10:00
Paper Time: 08:00
Venue: Boulevard C
First Author: : M.Buckle UK
Co Author(s): : A. Lee I. Stratton R. Healey A. Tufail R. Johnston
This study aimed to evaluate the incidence and prevalence of blindness, sight impairment and other visual acuity states in patients receiving ranibizumab for neovascular age-related macular degeneration (nAMD) in Gloucestershire.
Gloucestershire National Health Service Ophthalmology department.
Serial visual acuity (VA) and injection data for all treatment-naïve patients receiving their first intravitreal injections of ranibizumab for nAMD in the Gloucestershire National Health Service Ophthalmology department between 2008-2010 were extracted from an electronic medical record system. 610 patients were included in the study.
The prevalence of eligibility for certification of blindness (VA better-seeing eye 25 ETDRS letters or fewer at two consecutive visits or one visit with no further follow-up) at the time of first intravitreal injection was 0.8%, increasing to 3.5% after three years. The prevalence of eligibility for certification of sight impairment (VA better-seeing eye 26-39 ETDRS letters) increased from 4.1% at baseline to 5.5% after three years. The prevalence of vision sufficient to meet the criteria for holding a UK drivers’ licence (VA better-seeing eye 70 or more ETDRS letters) reduced from 57% at baseline to 48% after three years. The incidence of initiating ranibizumab treatment for nAMD in people aged 50 years and older in Gloucestershire was 111 people per 100 000 population in 2009, and 97 people in 2010. The incidence of eligibility for certification of blindness in patients aged 50 years and older with treated nAMD in Gloucestershire was 1.3 people per 100 000 population in 2009 and 3.5 people in 2010. The incidence of eligibility for certification of sight impairment in patients aged 50 years and older with treated nAMD in Gloucestershire was 8.5 people per 100 000 population in 2009 and 9.7 people in 2010.
This is the first real-world study on incidence and prevalence of eligibility for blindness and sight impairment in patients with treated nAMD in the UK based on visual acuity data. Only 3.6% of the treated population progressed to blindness in 2010.